PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12719774-5	2003	The binding activity of C-C2 to phosphatidylserine-containing phospholipid vesicles was measured by competitive binding with annexin V. The values of IC50 were approximately 70nM for both factor VIII and its light chain, but were about 7000nM for C-C2.	Phosphatidylserines	32-50	cytochrome c oxidase subunit 8A	Homo sapiens	195-199	
18435924-3	2008	We undertook an extended Cryo-electron microscopy study to follow the factor VIII binding to phosphatidylserine containing lipid nanotubes at different lipid composition.	Phosphatidylserines	93-111	cytochrome c oxidase subunit 8A	Homo sapiens	77-81	
6433504-2	1984	The addition of phospholipid vesicles containing phosphatidylserine and phosphatidylethanolamine to normal plasma and that of patients with von Willebrand"s disease resulted in the loss of almost two thirds of the factor VIII clotting antigen (VIII:CAg) measurable by IRMA.	Phosphatidylserines	49-67	cytochrome c oxidase subunit 8A	Homo sapiens	221-225	
7654192-0	1995	Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.	Phosphatidylserines	64-82	cytochrome c oxidase subunit 8A	Homo sapiens	36-40	
10933130-2	2000	The low bioavailability of subcutaneously administered factor VIII could have several causes: proteolytic degradation of the protein in the interstitium; adsorption to tissue, in particular to acidic phospholipids such as L-alpha phosphatidyl-L-serine (phosphatidylserine); the absence of free von Willebrand factor in the interstitium; phagocytosis by macrophages in the interstitium or in the lymph nodes; and coagulation could be initiated upon injection.	Phosphatidylserines	253-271	cytochrome c oxidase subunit 8A	Homo sapiens	62-66	
10933130-10	2000	Both the von Willebrand factor and phosphatidylserine/phosphatidylcholine (PS/PC) liposomes showed a significant stabilising effect on VIII:C in the tissue homogenates.	Phosphatidylserines	35-53	cytochrome c oxidase subunit 8A	Homo sapiens	135-139	
10933130-14	2000	Including phosphatidylserine in the formulations appeared to increase the availability, of subcutaneously administered r-VIII SQ in the pig.	Phosphatidylserines	10-28	cytochrome c oxidase subunit 8A	Homo sapiens	121-125	
1639816-3	1992	To evaluate the specificity of phosphatidylserine-containing membrane binding sites for factor VIII, we have developed a novel membrane model in which phospholipid bilayers are supported by glass microspheres (lipospheres).	Phosphatidylserines	31-49	cytochrome c oxidase subunit 8A	Homo sapiens	95-99	
1639816-4	1992	The binding of fluorescein-labeled factor VIII to lipospheres with membranes of 15% phosphatidylserine was equivalent to binding to phospholipid vesicles (KD = 4.8 nM).	Phosphatidylserines	84-102	cytochrome c oxidase subunit 8A	Homo sapiens	42-46	
1317308-6	1992	Structural features of both activated protein C and its substrates (coagulation factors V and VIII) are such that they require the localization of enzyme and substrate on the surface of phosphatidyl serine containing membranes for optimum activity.	Phosphatidylserines	186-205	cytochrome c oxidase subunit 8A	Homo sapiens	94-98	
6796129-2	1981	The binding of factor VIII to an equimolecular mixture of phosphatidylserine (PS) and phosphatidylcholine (PC) was studied by sucrose gradient ultracentrifugation (10-40% w/v saccharose in  0.01 M Tris-HC1/0.15 M NaCl buffer (pH 7).	Phosphatidylserines	58-76	cytochrome c oxidase subunit 8A	Homo sapiens	22-26	
6796129-2	1981	The binding of factor VIII to an equimolecular mixture of phosphatidylserine (PS) and phosphatidylcholine (PC) was studied by sucrose gradient ultracentrifugation (10-40% w/v saccharose in  0.01 M Tris-HC1/0.15 M NaCl buffer (pH 7).	Phosphatidylserines	78-80	cytochrome c oxidase subunit 8A	Homo sapiens	22-26